Answers are grounded in this paper and cite their sources.
Acute lymphoblastic leukemia (ALL) accounts for about one-third of childhood cancers and is driven by genetic disruption of lymphoid development. The Philadelphia chromosome–positive subtype, defined by BCR::ABL1 fusion, is linked to poorer outcomes. Data from the Kurdistan Region of Iraq are limited. This study aims to detect BCR::ABL1 fusion transcripts among a local cohort of B-ALL patients. Samples of peripheral blood and/or bone marrow were obtained from pediatric B-ALL patients (n = 82) before undergoing therapy, and healthy controls (n = 25) in Sulaymaniyah province, Kurdistan Region of Iraq. After hematological evaluation, total RNA was extracted, converted to cDNA, and screened for BCR::ABL1 fusion transcripts (p190 and p210) using reverse transcription Polymerase Chain Reaction (RT-PCR). Products were analyzed by capillary electrophoresis and Sanger sequencing. RT-PCR and capillary electrophoresis identified BCR::ABL1 fusion transcripts corresponding to e1a2 (521 bp), b2a2 (342 bp), and b3a2 (417 bp) variants. Among the pediatric B-ALL cases, BCR::ABL1 fusion transcripts were detected in 13.4% of the samples. The e1a2 transcript variant was identified in 4.9% of cases, while the b2a2 and b3a2 transcript variants were found in 6.1% and 2.4%, respectively. The results were further confirmed by Sanger sequencing; no fusion transcripts were detected in control samples. BCR::ABL1 transcript variants were identified in pediatric B-ALL cases in this cohort, with b2a2, e1a2, and b3a2 being the most frequent variants. Routine molecular screening may improve risk stratification, enable earlier detection, and guide targeted therapy.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: